BRPI0418181A - emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson - Google Patents

emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson

Info

Publication number
BRPI0418181A
BRPI0418181A BRPI0418181-6A BRPI0418181A BRPI0418181A BR PI0418181 A BRPI0418181 A BR PI0418181A BR PI0418181 A BRPI0418181 A BR PI0418181A BR PI0418181 A BRPI0418181 A BR PI0418181A
Authority
BR
Brazil
Prior art keywords
substituted
aminotetralines
morbus parkinson
prevent treatment
parkinson
Prior art date
Application number
BRPI0418181-6A
Other languages
English (en)
Inventor
Dieter Scheller
Frank Dressen
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BRPI0418181A publication Critical patent/BRPI0418181A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"EMPREGO DE 2-AMINOTETRALINAS SUBSTITUìDAS PARA PREVENçãO DO TRATAMENTO DE MORBUS PARKINSON". A presente invenção refere-se ao emprego de 2-aminotetralinas de fórmula geral (I) como medicamento para prevenção de Morbus Parkinson.
BRPI0418181-6A 2003-12-24 2004-12-23 emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson BRPI0418181A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10361258A DE10361258A1 (de) 2003-12-24 2003-12-24 Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
PCT/EP2004/014656 WO2005063238A1 (de) 2003-12-24 2004-12-23 Verwendung von substituierten 2-aminotetralinen zur vorbeugenden behandlung von morbus parkinson

Publications (1)

Publication Number Publication Date
BRPI0418181A true BRPI0418181A (pt) 2007-04-27

Family

ID=34706586

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418181-6A BRPI0418181A (pt) 2003-12-24 2004-12-23 emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson

Country Status (28)

Country Link
US (1) US8283376B2 (pt)
EP (1) EP1696905B1 (pt)
JP (1) JP5085938B2 (pt)
KR (1) KR20060125799A (pt)
CN (1) CN1897934B (pt)
AT (1) ATE389395T1 (pt)
AU (1) AU2004308649B2 (pt)
BR (1) BRPI0418181A (pt)
CA (1) CA2546797A1 (pt)
CY (1) CY1107956T1 (pt)
DE (2) DE10361258A1 (pt)
DK (1) DK1696905T3 (pt)
EA (1) EA011387B1 (pt)
ES (1) ES2303123T3 (pt)
HK (1) HK1094425A1 (pt)
HR (1) HRP20080175T3 (pt)
IL (1) IL175762A (pt)
IS (1) IS2517B (pt)
MX (1) MXPA06006693A (pt)
NO (1) NO20063275L (pt)
NZ (1) NZ547673A (pt)
PL (1) PL1696905T3 (pt)
PT (1) PT1696905E (pt)
RS (1) RS50578B (pt)
SI (1) SI1696905T1 (pt)
UA (1) UA83691C2 (pt)
WO (1) WO2005063238A1 (pt)
ZA (1) ZA200604114B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US8592477B2 (en) 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production
US8604242B2 (en) * 2008-10-13 2013-12-10 Interquim, S.A. Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
WO2011033252A1 (en) * 2009-09-16 2011-03-24 United Arab Emirates University Diagnostic agent for parkinson's disease
KR20120107075A (ko) 2009-10-16 2012-09-28 에파이오메드 테라퓨틱스, 아이엔씨. 구토 치료
HUE039447T2 (hu) 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649300A5 (de) * 1981-08-07 1985-05-15 Sandoz Ag Ergopeptinderivate, ihre herstellung und verwendung.
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
ES2032570T3 (es) * 1987-11-20 1993-02-16 Farmitalia Carlo Erba S.R.L. Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
DE3827561C1 (pt) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
WO1990015047A1 (en) * 1989-05-31 1990-12-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
SE9301732D0 (sv) 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
TW280819B (pt) * 1993-11-17 1996-07-11 Sumitomo Pharma
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
IT1276522B1 (it) 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5807570A (en) 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6010877A (en) * 1997-01-10 2000-01-04 Smithkline Beecham Corporation cDNA clone HE8CS41 that encodes a novel 7-transmembrane receptor
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US6242572B1 (en) 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
IT1292155B1 (it) * 1997-06-13 1999-01-25 Zambon Spa Derivati naftotiazolonici attivi sul recettore dopaminergico d 3
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
AU754062B2 (en) 1998-07-03 2002-10-31 Innogenetics N.V. Differential diagnosis of neurodegeneration
GB9815618D0 (en) 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
CO5111024A1 (es) * 1998-12-29 2001-12-26 Kimberly Clark Co Composiciones de recubrimientos de polimero disparado por ion sobre peliculas de polimero sensibles al agua
US6372920B1 (en) 1999-11-23 2002-04-16 Aderis Pharmaceuticals, Inc. Process for preparing nitrogen-substituted aminotetralins
US20020110585A1 (en) 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6227875B1 (en) * 1999-12-27 2001-05-08 Hon Hai Precision Ind. Co., Ltd. Connector assembly for vertically mounted hard disk drive
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1332363A4 (en) 2000-10-09 2007-08-29 Kay Double PROOF OF NEURODEGENERATIVE DISEASES
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
EP1256339B1 (en) 2001-05-08 2003-10-15 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
EP1418834A4 (en) 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
FR2828212B1 (fr) 2001-08-03 2003-10-31 Aventis Pharma Sa Methodes de diagnostic et de pronostic de la maladie de parkinson
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
CN101822676A (zh) * 2002-01-28 2010-09-08 协和发酵麒麟株式会社 治疗运动疾病患者的方法
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
AU2002339230A1 (en) 2002-03-08 2003-09-22 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
MXPA04009352A (es) * 2002-04-18 2005-01-25 Pharmacia Corp Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1426049B1 (en) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EA200700368A1 (ru) 2004-08-02 2007-08-31 Шварц Фарма Аг Карбоксамиды индолизина и их аза- и диазапроизводных
WO2006039532A2 (en) 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US8592477B2 (en) * 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production

Also Published As

Publication number Publication date
JP2007518715A (ja) 2007-07-12
US8283376B2 (en) 2012-10-09
WO2005063238A1 (de) 2005-07-14
IS2517B (is) 2009-06-15
AU2004308649A1 (en) 2005-07-14
UA83691C2 (ru) 2008-08-11
IL175762A0 (en) 2008-04-13
CN1897934A (zh) 2007-01-17
CN1897934B (zh) 2010-05-12
IS8485A (is) 2006-05-26
SI1696905T1 (sl) 2008-08-31
CA2546797A1 (en) 2005-07-14
ZA200604114B (en) 2007-08-29
DE502004006619D1 (de) 2008-04-30
PL1696905T3 (pl) 2008-08-29
NO20063275L (no) 2006-07-14
IL175762A (en) 2013-01-31
EP1696905A1 (de) 2006-09-06
NZ547673A (en) 2011-02-25
PT1696905E (pt) 2008-06-09
EA200600971A1 (ru) 2006-12-29
EP1696905B1 (de) 2008-03-19
RS50578B (sr) 2010-05-07
EA011387B1 (ru) 2009-02-27
DK1696905T3 (da) 2008-06-30
JP5085938B2 (ja) 2012-11-28
HK1094425A1 (en) 2007-03-30
KR20060125799A (ko) 2006-12-06
DE10361258A1 (de) 2005-07-28
ES2303123T3 (es) 2008-08-01
HRP20080175T3 (en) 2008-06-30
MXPA06006693A (es) 2006-08-31
CY1107956T1 (el) 2013-03-13
US20080146622A1 (en) 2008-06-19
AU2004308649B2 (en) 2010-08-26
ATE389395T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
BR0311494A (pt) Novos indóis substituìdos
HK1094421A1 (en) (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist
GB0318447D0 (en) Therapeutic agents
EA201000050A1 (ru) Замещенные бициклолактамные соединения
SI2150530T1 (sl) Substituirani sulfonamidni derivati
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
HK1110211A1 (pt)
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
MX2010001304A (es) Compuestos terapeuticos.
SE0002739D0 (sv) New use
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
ECSP045157A (es) Derivados de azaindolilalquilamina como ligandos 5-hidroxitriptamina-6
UY29311A1 (es) Agentes terapeuticos
UY29310A1 (es) Agentes terapéuticos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB PHARMA GMBH (DE)

Free format text: NOME ALTERADO DE: SCHWARZ PHARMA AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.